Regeneron reports Q2 revenue of $4.29B and positive 84-week Phase 3 data for Pasatru
FROM THE WIRE · FINANCE.YAHOO.COM
Regeneron Pharmaceuticals reported Q2 revenue of US$4.29b, up 16.7% year on year, alongside positive 84 week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva. The data supports its recently approved use in reducing new heterotopic ossification…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishQuarterly revenue growth and positive trial data could strengthen the rare disease franchise.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Regeneron reported second-quarter revenue of $4.29 billion, up 16.7% year on year.
- 02The 84-week OPTIMA data on Pasatru show a sustained effect in limiting new heterotopic ossification lesions.
- 03The safety profile appears generally consistent across the extended readout.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets